OR WAIT null SECS
Takeda Pharmaceutical Company and enGene have entered into a strategic alliance to develop novel therapies for specialty gastrointestinal diseases.
Takeda Pharmaceutical Company and enGene have entered into a strategic alliance to discover, develop, and commercialize novel therapies for specialty gastrointestinal (GI) diseases using enGene’s Gene Pill gene delivery platform.
Under the terms of the agreement, enGene will develop up to two undisclosed targets selected by Takeda through preclinical proof of concept and investigational new drug enabling studies. Takeda will then have an option to exclusively license the global rights for the product candidates.
Following option exercise, Takeda will be responsible for all clinical development and commercialization of those products. enGene will receive an upfront payment and reimbursement of all R&D costs incurred during the development of the selected targets. enGene is eligible to earn milestone payments for the product candidates based on accomplishment of specific research, clinical, regulatory, and commercial milestones and will receive tiered royalties on future net sales of the collaboration products. Takeda will also collaborate with enGene in developing Gene Pill into a platform for oral delivery of antibodies. Takeda has the exclusive option to obtain a right of first negotiation for up to three antibody targets.
Source: Takeda Pharmaceuticals